Congenital Hemolytic Anemia Treatments
Find Congenital Hemolytic Anemia Treatments
Brand Name
Oxbryta
Generic Name
Voxelotor
View Brand Information FDA approval date: November 25, 2019
Classification: Hemoglobin S Polymerization Inhibitor
Form: Tablet
What is Oxbryta (Voxelotor)?
OXBRYTA is indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial. OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment